DEFA14A ·Filed Apr 30, 2026

PYXS

Pyxis Oncology, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago SEC0001193125-26-194051
Proxy solicitation materials
Actionable Insight • Neutral

Routine proxy notice — no trading signal. Monitor the June 11 meeting for any unexpected voting outcomes or dissident activity, though none is indicated in this filing.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
PYXS ▲ +71.18% at T+60d
NEUTRAL call ✓ call won +71.18% · α vs SPY +68.07% · entry $1.70 → $2.91
Entry anchored
Apr 30, 2026
via day open
T+1d
+1.18%
call +1.18% · α +0.96%
$1.72
settled 5mo ago
T+5d
+32.94%
call +32.94% · α +31.21%
$2.26
settled 5mo ago
T+20d
+5.88%
call +5.88% · α +0.66%
$1.80
settled 4mo ago
T+60d
+71.18%
call +71.18% · α +68.07%
$2.91
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Pyxis Oncology filed a DEFA14A notice of internet availability of proxy materials for its 2024 Annual Meeting of Stockholders, scheduled for June 11, 2024. The agenda includes the election of one Class I director and three Class III directors, and ratification of Ernst & Young as independent auditor. The board recommends a vote FOR all proposals. This is a routine administrative filing with no material financial impact.

Key Facts

  • Annual Meeting of Stockholders scheduled for June 11, 2024
  • Record date: April 18, 2024
  • Proposal 1: Election of one Class I director (Santhosh Palani) and three Class III directors (John Flavin, Lara Sullivan, Jakob Dupont)
  • Proposal 2: Ratification of Ernst & Young LLP as independent auditor for FY 2024
  • Board recommends a vote FOR both proposals
  • Filing is a notice of internet availability of proxy materials (DEFA14A)

Financial Impact

No financial figures disclosed in this filing

Risk Factors

  • No material risks identified from this routine filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-194051
Document: 0001193125-26-194051-index-headers.html0001193125-26-194051
Document: 0001193125-26-194051-index.html0001193125-26-194051
Document: 0001193125-26-194051.txt0001193125-26-194051
12 reports for PYXS
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +42.94%Apr 17, 2026
Filters
Rows
Reports for PYXS — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
8-K
BULLISH ★ 6/10
$3.38 $3.34▼ −1.18%▼ −0.09%$2.14 (−36.69%)
Sep 8, 2026
24d ago
8-K
NEUTRAL ★ 3/10
$3.89 $3.33▼ −14.40%▼ −13.28%$2.14 (−44.99%)
Aug 28, 2026
5w ago
EFFECT
BEARISH ★ 6/10
$3.23 $3.89▼ −20.43%▼ −20.32%$2.14 (+33.75%)
Aug 13, 2026
7w ago
8-K
MIXED ★ 5/10
$3.01 $3.12▲ +3.65%▲ +5.62%$2.14 (−28.90%)
Jul 2, 2026
13w ago
8-K
MIXED ★ 6/10
$2.63 $2.64▲ +0.38%▼ −0.55%$2.14 (−18.63%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 2/10
$2.85 $3.07▲ +7.72%▲ +7.46%$2.14 (−24.91%)
Jun 30, 2026
13w ago
Press Release
MIXED ★ 6/10
$3.01 $2.46▼ −18.27%▼ −18.88%$2.14 (−28.90%)
May 14, 2026
20w ago
8-K
NEUTRAL ★ 5/10
$2.21 $1.94▼ −12.22%▼ −11.50%$2.14 (−3.17%)
May 14, 2026
20w ago
Press Release
NEUTRAL ★ 4/10
$2.21 $1.94▼ −12.22%▼ −11.50%$2.14 (−3.17%)
Apr 30, 2026
22w ago
DEFA14A
NEUTRAL ★ 2/10
$1.70 $2.26▲ +32.94%▲ +31.21%$2.14 (+25.88%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (64h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access